CoChat
Sign Up
Cited by 180

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Oxidized cholesterol as the driving force behind the development of Alzheimer’s disease

Gamba, Paola, Testa, Gabriella, Gargiulo, Simona, Staurenghi, Erica, Poli, Giuseppe, Leonarduzzi, Gabriella·2015·Frontiers in Aging Neuroscience
DOI 10.3389/fnagi.2015.00119PMC PMC4473000
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnagi.2015.00119

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 251

  1. Abbas N. Bednar I. Mix E. Marie S. Paterson D. Ljungberg A.. (2002). Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. J. Neuroimmunol. 126, 50– 57. 10.1016/s0165-5728(02)00050-4 12020956 · DOI
  2. Abildayeva K. Jansen P. J. Hirsch-Reinshagen V. Bloks V. W. Bakker A. H. Ramaekers F. C.. (2006). 24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. J. Biol. Chem. 281, 12799– 12808. 10.1074/jbc.m601019200 16524875 · DOI · Paper page
  3. Acarin L. González B. Castellano B. (2000). Neuronal, astroglial and microglial cytokine expression after an excitotoxic lesion in the immature rat brain. Eur. J. Neurosci. 12, 3505– 3520. 10.1046/j.1460-9568.2000.00226.x 11029620 · DOI
  4. Ahonen L. Maire F. B. Savolainen M. Kopra J. Vreeken R. J. Hankemeier T.. (2014). Analysis of oxysterols and vitamin D metabolites in mouse brain and cell line samples by ultra-high-performance liquid chromatography-atmospheric pressure photoionization-mass spectrometry. J. Chromatogr. A. 1364, 214– 222. 10.1016/j.chroma.2014.08.088 25204266 · DOI
  5. Arispe N. Doh M. (2002). Plasma membrane cholesterol controls the cytotoxicity of Alzheimer’s disease AbetaP (1-40) and (1-42) peptides. FASEB J. 16, 1526– 1536. 10.1096/fj.02-0829com 12374775 · DOI
  6. Azizi G. Mirshafiey A. (2012). The potential role of proinflammatory and antiinflammatory cytokines in Alzheimer disease pathogenesis. Immunopharmacol. Immunotoxicol. 34, 881– 895. 10.3109/08923973.2012.705292 22970774 · DOI
  7. Bales K. R. Verina T. Cummins D. J. Du Y. Dodel R. C. Saura J.. (1999). Apolipoprotein E is essential for amyloid deposition in the APP (V717F) transgenic mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. U S A 96, 15233– 15238. 10.1073/pnas.96.26.15233 10611368 PMC24803 · DOI · Paper page
  8. Beel A. J. Sakakura M. Barrett P. J. Sanders C. R. (2010). Direct binding of cholesterol to the amyloid precursor protein: An important interaction in lipid-Alzheimer’s disease relationships? Biochim Biophys. Acta 1801, 975– 982. 10.1016/j.bbalip.2010.03.008 20304095 PMC2886191 · DOI
  9. Berthier A. Lemaire-Ewing S. Prunet C. Monier S. Athias A. Bessède G.. (2004). Involvement of a calcium-dependent dephosphorylation of BAD associated with the localization of Trpc-1 within lipid rafts in 7-ketocholesterol-induced THP-1 cell apoptosis. Cell Death Differ. 11, 897– 905. 10.1038/sj.cdd.4401434 15105836 · DOI
  10. Bhattacharyya R. Kovacs D. M. (2010). ACAT inhibition and amyloid beta reduction. Biochim. Biophys. Acta 1801, 960– 965. 10.1016/j.bbalip.2010.04.003 20398792 PMC2918257 · DOI · Paper page
  11. Björkhem I. (2006). Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J. Intern. Med. 260, 493– 508. 10.1111/j.1365-2796.2006.01725.x 17116000 · DOI
  12. Björkhem I. Meaney S. (2004). Brain cholesterol: long secret life behind a barrier. Arterioscler. Thromb. Vasc. Biol. 24, 806– 815. 10.1161/01.atv.0000120374.59826.1b 14764421 · DOI · Paper page
  13. Björkhem I. Cedazo-Minguez A. Leoni V. Meaney S. (2009). Oxysterols and neurodegenerative diseases. Mol. Aspects Med. 30, 171– 179. 10.1016/j.mam.2009.02.001 19248803 · DOI · Paper page
  14. Bogdanovic N. Bretillon L. Lund E. G. Diczfalusy U. Lannfelt L. Winblad B.. (2001). On the turnover of brain cholesterol in patients with Alzheimer’s disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells. Neurosci. Lett. 314, 45– 48. 10.1016/s0304-3940(01)02277-7 11698143 · DOI
  15. Bonda D. J. Wang X. Perry G. Nunomura A. Tabaton M. Zhu X.. (2010). Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology 59, 290– 294. 10.1016/j.neuropharm.2010.04.005 20394761 · DOI
  16. Brecht W. J. Harris F. M. Chang S. Tesseur I. Yu G. Q. Xu Q.. (2004). Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J. Neurosci. 24, 2527– 2534. 10.1523/jneurosci.4315-03.2004 15014128 PMC6729489 · DOI · Paper page
  17. Bretillon L. Sidén A. Wahlund L. O. Lütjohann D. Minthon L. Crisby M.. (2000). Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. Neurosci. Lett. 293, 87– 90. 10.1016/s0304-3940(00)01466-x 11027840 · DOI
  18. Brown G. C. Bal-Price A. (2003). Inflammatory neurodegeneration mediated by nitric oxide, glutamate and mitochondria. Mol. Neurobiol. 27, 325– 355. 10.1385/mn:27:3:325 12845153 · DOI
  19. Brown J. 3rd Theisler C. Silberman S. Magnuson D. Gottardi-Littell N. Lee J. M.. (2004). Differential expression of cholesterol hydroxylases in Alzheimer’s disease. J. Biol. Chem. 279, 34674– 34681. 10.1074/jbc.m402324200 15148325 · DOI
  20. Braak H. Del Tredici K. (2004). Alzheimer’s disease: intraneuronal alterations precede insoluble amyloid-beta formation. Neurobiol. Aging 25, 713– 718. 10.1016/j.neurobiolaging.2003.12.015 15165692 · DOI
  21. Burns M. P. Noble W. J. Olm V. Gaynor K. Casey E. LaFrancois J.. (2003b). Co-localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques. Brain Res. Mol. Brain Res. 110, 119– 125. 10.1016/s0169-328x(02)00647-2 12573540 · DOI
  22. Burns M. Gaynor K. Olm V. Mercken M. LaFrancois J. Wang L.. (2003a). Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. J. Neurosci. 23, 5645– 5649. 12843267 PMC6741250
  23. Butterfield D. A. Boyd-Kimball D. (2005). The critical role of methionine 35 in Alzheimer’s amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity. Biochim. Biophys. Acta 1703, 149– 156. 10.1016/j.bbapap.2004.10.014 15680223 · DOI
  24. Butterfield D. A. Kanski J. (2001). Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech. Ageing Dev. 122, 945– 962. 10.1016/s0047-6374(01)00249-4 11348660 · DOI
  25. Butterfield D. A. Drake J. Pocernich C. Castegna A. (2001). Evidence of oxidative damage in Alzheimer’s disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 7, 548– 554. 10.1016/s1471-4914(01)02173-6 11733217 · DOI · Paper page
  26. Butterfield D. A. Swomley A. M. Sultana R. (2013). Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid. Redox Signal. 19, 823– 835. 10.1089/ars.2012.5027 23249141 PMC3749710 · DOI · Paper page
  27. Cam J. A. Bu G. (2006). Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family. Mol. Neurodegener. 18, 1– 8. 10.1186/1750-1326-1-8 16930455 PMC1563464 · DOI · Paper page
  28. Canepa E. Borghi R. Viña J. Traverso N. Gambini J. Domenicotti C.. (2011). Cholesterol and amyloid-A: evidence for a cross-talk between astrocytes and neuronal cells. J. Alzheimers Dis. 25, 645– 653. 10.3233/JAD-2011-110053 21483097 · DOI
  29. Cao G. Bales K. R. DeMattos R. B. Paul S. M. (2007). Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer’s disease therapeutics. Curr. Alzheimer Res. 4, 179– 184. 10.2174/156720507780362173 17430244 · DOI · Paper page
  30. Carter D. B. Dunn E. McKinley D. D. Stratman N. C. Boyle T. P. Kuiper S. L.. (2001). Human apolipoprotein E4 accelerates beta-amyloid deposition in APPsw transgenic mouse brain. Ann. Neurol. 50, 468– 475. 10.1002/ana.1134 11601499 · DOI
  31. Castellani R. J. Rolston R. K. Smith M. A. (2010). Alzheimer disease. Dis. Mon. 56, 484– 546. 10.1016/j.disamonth.2010.06.001 20831921 PMC2941917 · DOI
  32. Castellani R. Hirai K. Aliev G. Drew K. L. Nunomura A. Takeda A.. (2002). Role of mitochondrial dysfunction in Alzheimer’s disease. J. Neurosci. Res. 70, 357– 360. 10.1002/jnr.10389 12391597 · DOI
  33. Chan S. L. Kim W. S. Kwok J. B. Hill A. F. Cappai R. Rye K. A.. (2008). ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. J. Neurochem. 106, 793– 804. 10.1111/j.1471-4159.2008.05433.x 18429932 · DOI
  34. Chopra K. Misra S. Kuhad A. (2011). Current perspectives on pharmacotherapy of Alzheimer’s disease. Expert Opin. Pharmacother. 12, 335– 350. 10.1517/14656566.2011.520702 21222549 · DOI
  35. Churchward M. A. Todd K. G. (2014). Statin treatment affects cytokine release and phagocytic activity in primary cultured microglia through two separable mechanisms. Mol. Brain 7: 85. 10.1186/s13041-014-0085-7 25424483 PMC4247600 · DOI
  36. Colton C. Wilcock D. M. (2010). Assessing activation states in microglia. CNS Neurol. Disord. Drug Targets 9, 174– 191. 10.2174/187152710791012053 20205642 · DOI
  37. Combs C. K. Karlo J. C. Kao S. C. Landreth G. E. (2001). β-amyloid stimulation of microglia anti monocytes results in TNFα-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci. 21, 1179– 1188. 11160388 PMC6762255
  38. Cordy J. M. Hooper N. M. Turner A. J. (2006). The involvement of lipid rafts in Alzheimer’s disease. Mol. Membr. Biol. 23, 111– 122. 10.1080/09687860500496417 16611586 · DOI · Paper page
  39. Cottrell D. A. Blakely E. L. Johnson M. A. Ince P. G. Turnbull D. M. (2001). Mitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD. Neurology 57, 260– 264. 10.1212/wnl.57.2.260 11468310 · DOI
  40. Crick P. J. Beckers L. Baes M. Van Veldhoven P. P. Wang Y. Griffiths W. J. (2015a). The oxysterol and cholestenoic acid profile of mouse cerebrospinal fluid. Steroids [Epub ahead of print] 10.1016/j.steroids.2015.02.021 25759118 PMC4503871 · DOI
  41. Crick P. J. William Bentley T. Abdel-Khalik J. Matthews I. Clayton P. T. Morris A. A.. (2015b). Quantitative charge-tags for sterol and oxysterol analysis. Clin. Chem. 61, 400– 411. 10.1373/clinchem.2014.231332 25512642 · DOI
  42. Curtain C. C. Ali F. E. Smith D. G. Bush A. I. Masters C. L. Barnham K. J. (2003). Metal ions, pH and cholesterol regulate the interactions of Alzheimer’s disease amyloid-beta peptide with membrane lipid. J. Biol. Chem. 278, 2977– 2982. 10.1074/jbc.m205455200 12435742 · DOI
  43. D’Andrea M. R. Cole G. M. Ard M. D. (2004). The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol. Aging 25, 675– 683. 10.1016/j.neurobiolaging.2003.12.026 15172747 · DOI · Paper page
  44. Dasari B. Prasanthi J. R. Marwarha G. Singh B. B. Ghribi O. (2010). The oxysterol 27-hydroxycholesterol increases β-amyloid and oxidative stress in retinal pigment epithelial cells. BMC Ophthalmol. 10: 22. 10.1186/1471-2415-10-22 20836858 PMC2946278 · DOI
  45. DeGiorgio L. A. Shimizu Y. Chun H. S. Kim Y. S. Sugama S. Son J. H.. (2002). Amyloid precursor protein gene disruption attenuates degeneration of substantia nigra compacta neurons following axotomy. Brain Res. 938, 38– 44. 10.1016/s0006-8993(02)02483-6 12031533 · DOI
  46. Dias I. H. Polidori M. C. Griffiths H. R. (2014). Hypercholesterolaemia-induced oxidative stress at the blood-brain barrier. Biochem. Soc. Trans. 42, 1001– 1005. 10.1042/BST20140164 25109993 · DOI
  47. Diczfalusy U. (2013). On the formation and possible biological role of 25-hydroxycholesterol. Biochimie 95, 455– 460. 10.1016/j.biochi.2012.06.016 22732193 · DOI · Paper page
  48. Ding Q. Dimayuga E. Keller J. N. (2007). Oxidative damage, protein synthesis and protein degradation in Alzheimer’s disease. Curr. Alzheimer Res. 4, 73– 79. 10.2174/156720507779939788 17316168 · DOI
  49. Drouin-Ouellet J. Cicchetti F. (2012). Inflammation and neurodegeneration: the story ‘retolled’. Trends Pharmacol. Sci. 33, 542– 551. 10.1016/j.tips.2012.07.002 22944460 · DOI
  50. Du H. Guo L. Yan S. Sosunov A. A. McKhann G. M. Yan S. S. (2010). Early deficits in synaptic mitochondria in an Alzheimer’s disease mouse model. Proc. Natl. Acad. Sci. U S A 107, 18670– 18675. 10.1073/pnas.1006586107 20937894 PMC2972922 · DOI · Paper page
  51. Ehehalt R. Keller P. Haass C. Thiele C. Simons K. (2003). Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell. Biol. 160, 113– 123. 10.1083/jcb.200207113 12515826 PMC2172747 · DOI · Paper page
  52. Evans R. M. Hui S. Perkins A. Lahiri D. K. Poirier J. Farlow M. R. (2004). Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology 62, 1869– 1871. 10.1212/01.wnl.0000125323.15458.3f 15159498 · DOI
  53. Famer D. Meaney S. Mousavi M. Nordberg A. Björkhem I. Crisby M. (2007). Regulation of alpha- and beta-secretase activity by oxysterols: cerebrosterol stimulates processing of APP via the alpha-secretase pathway. Biochem. Biophys. Res. Commun. 359, 46– 50. 10.1016/j.bbrc.2007.05.033 17532301 · DOI
  54. Fan Q. W. Yu W. Senda T. Yanagisawa K. Michikawa M. (2001). Cholesterol-dependent modulation of tau phosphorylation in cultured neurons. J. Neurochem. 76, 391– 400. 10.1046/j.1471-4159.2001.00063.x 11208902 · DOI
  55. Fantini J. Yahi N. (2010). Molecular insights into amyloid regulation by membrane cholesterol and sphingolipids: common mechanisms in neurodegenerative diseases. Expert Rev. Mol. Med. 12: e27. 10.1017/s1462399410001602 20807455 PMC2931503 · DOI
  56. Fassbender K. Masters C. Beyreuther K. (2000). Alzheimer’s disease: an inflammatory disease? Neurobiol. Aging 21, 433– 436. 10.1016/S0197-4580(00)00147-0 10858589 · DOI
  57. Fassbender K. Simons M. Bergmann C. Stroick M. Lütjohann D. Keller P.. (2001). Simvastatin strongly reduces levels of Alzheimer’s disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U S A 98, 5856– 5861. 10.1073/pnas.081620098 11296263 PMC33303 · DOI · Paper page
  58. Ferrera P. Mercado-Gómez O. Silva-Aguilar M. Valverde M. Arias C. (2008). Cholesterol potentiates beta-amyloid-induced toxicity in human neuroblastoma cells: involvement of oxidative stress. Neurochem. Res. 33, 1509– 1517. 10.1007/s11064-008-9623-y 18288607 · DOI
  59. Ferretti M. T. Cuello A. C. (2011). Does a pro-inflammatory process precede Alzheimer’s disease and mild cognitive impairment? Curr. Alzheimer Res. 8, 164– 174. 10.2174/1567211213451702050 21345170 · DOI
  60. Figueiredo-Pereira M. E. Rockwell P. Schmidt-Glenewinkel T. Serrano P. (2015). Neuroinflammation and J2 prostaglandins: linking impairment of the ubiquitin-proteasome pathway and mitochondria to neurodegeneration. Front. Mol. Neurosci. 7: 104. 10.3389/fnmol.2014.00104 25628533 PMC4292445 · DOI
  61. Findeis M. A. (2007). The role of amyloid β peptide 42 in Alzheimer’s disease. Pharmacol. Ther. 116, 266– 286. 10.1016/j.pharmthera.2007.06.006 17716740 · DOI
  62. Fitz N. F. Cronican A. Pham T. Fogg A. Fauq A. H. Chapman R.. (2010). LXR agonist treatment ameliorates amyloid pathology and memory deficits caused by high fat diet in APP23 mice. J. Neurosci. 30, 6862– 6872. 10.1523/JNEUROSCI.1051-10.2010 20484628 PMC2883862 · DOI · Paper page
  63. Gamba P. Guglielmotto M. Testa G. Monteleone D. Zerbinati C. Gargiulo S.. (2014). Up-regulation of β-amyloidogenesis in neuron-like human cells by both 24- and 27-hydroxycholesterol: protective effect of N-acetyl-cysteine. Aging Cell. 13, 561– 572. 10.1111/acel.12206 24612036 PMC4326893 · DOI
  64. Gamba P. Leonarduzzi G. Tamagno E. Guglielmotto M. Testa G. Sottero B.. (2011). Interaction between 24-hydroxycholesterol, oxidative stress and amyloid-β in amplifying neuronal damage in Alzheimer’s disease: three partners in crime. Aging Cell 10, 403– 417. 10.1111/j.1474-9726.2011.00681.x 21272192 · DOI
  65. Gamba P. Testa G. Sottero B. Gargiulo S. Poli G. Leonarduzzi G. (2012). The link between altered cholesterol metabolism and Alzheimer’s disease. Ann. N Y Acad. Sci. 1259, 54– 64. 10.1111/j.1749-6632.2012.06513.x 22758637 · DOI
  66. Gatz M. Reynolds C. A. Fratiglioni L. Johansson B. Mortimer J. A. Berg S.. (2006). Role of genes and environments for explaining Alzheimer disease. Arch. Gen. Psychiatry 63, 168– 174. 10.1001/archpsyc.63.2.168 16461860 · DOI · Paper page
  67. Ghribi O. Larsen B. Schrag M. Herman M. M. (2006). High cholesterol content in neurons increases BACE, A-amyloid and phosphorylated tau levels in rabbit hippocampus. Exp. Neurol. 200, 460– 467. 10.1016/j.expneurol.2006.03.019 16696972 · DOI · Paper page
  68. Glass C. K. Saijo K. Winner B. Marchetto M. C. Gage F. H. (2010). Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918– 934. 10.1016/j.cell.2010.02.016 20303880 PMC2873093 · DOI · Paper page
  69. Gong J. S. Sawamura N. Zou K. Sakai J. Yanagisawa K. Michikawa M. (2002). Amyloid beta-protein affects cholesterol metabolism in cultured neurons: implications for pivotal role of cholesterol in the amyloid cascade. J. Neurosci. Res. 70, 438– 446. 10.1002/jnr.10347 12391604 · DOI
  70. Götz J. Chen F. van Dorpe J. Nitsch R. M. (2001). Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293, 1491– 1495. 10.1126/science.1062097 11520988 · DOI · Paper page
  71. Grimm M. O. Grimm H. S. Tomic I. Beyreuther K. Hartmann T. Bergmann C. (2008). Independent inhibition of Alzheimer disease beta- and gamma-secretase cleavage by lowered cholesterol levels. J. Biol. Chem. 283, 11302– 11311. 10.1074/JBC.M801520200 18308724 · DOI
  72. Harris B. Pereira I. Parkin E. (2009). Targeting ADAM10 to lipid rafts in neuroblastoma SH-SY5Y cells impairs amyloidogenic processing of the amyloid precursor protein. Brain Res. 1296, 203– 215. 10.1016/j.brainres.2009.07.105 19679113 · DOI
  73. Harris F. M. Brecht W. J. Xu Q. Tesseur I. Kekonius L. Wyss-Coray T.. (2003). Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer’s disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc. Natl. Acad. Sci. U S A 100, 10966– 10971. 10.1073/pnas.1434398100 12939405 PMC196910 · DOI · Paper page
  74. Harris J. R. (2008). Cholesterol binding to amyloid-beta fibrils: a TEM study. Micron 39, 1192– 1196. 10.1016/j.micron.2008.05.001 18586500 · DOI
  75. Hascalovici J. R. Vaya J. Khatib S. Holcroft C. A. Zukor H. Song W.. (2009). Brain sterol dysregulation in sporadic AD and MCI: relationship to heme oxygenase-1. J. Neurochem. 110, 1241– 1253. 10.1111/j.1471-4159.2009.06213.x 19522732 PMC2770254 · DOI
  76. He X. Jenner A. M. Ong W. Y. Farooqui A. A. Patel S. C. (2006). Lovastatin modulates increased cholesterol and oxysterol levels and has a neuroprotective effect on rat hippocampal neurons after kainate injury. J. Neuropathol. Exp. Neurol. 65, 652– 663. 10.1097/01.jnen.0000225906.82428.69 16825952 · DOI
  77. Head E. Lott I. T. Cribbs D. H. Cotman C. W. Rohn T. T. (2002). Beta-amyloid deposition and neurofibrillary tangle association with caspase activation in Down syndrome. Neurosci. Lett. 330, 99– 103. 10.1016/s0304-3940(02)00705-x 12213643 · DOI
  78. Heneka M. T. O’Banion M. K. (2007). Inflammatory processes in Alzheimer’s disease. J. Neuroimmunol. 184, 69– 91. 10.1016/j.jneuroim.2006.11.017 17222916 · DOI · Paper page
  79. Herz J. Beffert U. (2000). Apolipoprotein E receptors: linking brain development and Alzheimer’s disease. Nat. Rev. Neurosci. 1, 51– 58. 10.1038/35036221 11252768 · DOI
  80. Heverin M. Bogdanovic N. Lütjohann D. Bayer T. Pikuleva I. Bretillon L.. (2004). Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer’s disease. J. Lipid Res. 45, 186– 193. 10.1194/jlr.m300320-jlr200 14523054 · DOI
  81. Heverin M. Meaney S. Lütjohann D. Diczfalusy U. Wahren J. Björkhem I. (2005). Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J. Lipid Res. 46, 1047– 1052. 10.1194/jlr.m500024-jlr200 15741649 · DOI
  82. Holmes C. (2013). Review: systemic inflammation and Alzheimer’s disease. Neuropathol. Appl. Neurobiol. 39, 51– 68. 10.1111/j.1365-2990.2012.01307.x 23046210 · DOI · Paper page
  83. Holmes C. Butchart J. (2011). Systemic inflammation and Alzheimer’s disease. Biochem. Soc. Trans. 39, 898– 901. 10.1042/BST0390898 21787320 · DOI
  84. Holtzman D. M. Bales K. R. Tenkova T. Fagan A. M. Parsadanian M. Sartorius L. J.. (2000). Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. U S A 97, 2892– 2897. 10.1073/pnas.050004797 10694577 PMC16026 · DOI · Paper page
  85. Hooijmans C. R. Rutters F. Dederen P. J. Gambarota G. Veltien A. van Groen T.. (2007). Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched Typical Western Diet (TWD). Neurobiol. Dis. 28, 16– 29. 10.1016/j.nbd.2007.06.007 17720508 · DOI
  86. Hughes T. M. Kuller L. H. Lopez O. L. Becker J. T. Evans R. W. Sutton-Tyrrell K.. (2012). Markers of cholesterol metabolism in the brain show stronger association with cerebrovascular disease than Alzheimer’s disease. J. Alzheimers Dis. 30, 53– 61. 10.3233/JAD-2012-111460 22377780 PMC3348402 · DOI
  87. Hughes T. M. Lopez O. L. Evans R. W. Kamboh M. I. Williamson J. D. Klunk W. E.. (2014). Markers of cholesterol transport are associated with amyloid deposition in the brain. Neurobiol. Aging 35, 802– 807. 10.1016/j.neurobiolaging.2013.09.040 24199960 PMC3896052 · DOI
  88. Hughes T. M. Rosano C. Evans R. W. Kuller L. H. (2013). Brain cholesterol metabolism, oxysterols and dementia. J. Alzheimers Dis. 33, 891– 911. 10.3233/JAD-2012-121585 23076077 PMC4354887 · DOI
  89. Iuliano L. (2011). Pathways of cholesterol oxidation via non-enzymatic mechanisms. Chem. Phys. Lipids 164, 457– 458. 10.1016/j.chemphyslip.2011.06.006 21703250 · DOI
  90. Iuliano L. Crick P. J. Zerbinati C. Tritapepe L. Abdel-Khalik J. Poirot M.. (2015). Cholesterol metabolites exported from human brai. Steroids [Epub ahead of print] 10.1016/j.steroids.2015.01.026 25668615 PMC4503873 · DOI
  91. Iuliano L. Monticolo R. Straface G. Spoletini I. Gianni W. Caltagirone C.. (2010). Vitamin E and enzymatic/oxidative stress-driven oxysterols in amnestic mild cognitive impairment subtypes and Alzheimer’s disease. J. Alzheimers Dis. 21, 1383– 1392. 10.3233/JAD-2010-100780 21504117 · DOI
  92. Jacob K. D. Noren Hooten N. Trzeciak A. R. Evans M. K. (2013). Markers of oxidant stress that are clinically relevant in aging and age-related disease. Mech. Ageing Dev. 134, 139– 157. 10.1016/j.mad.2013.02.008 23428415 PMC3664937 · DOI
  93. Jang E. R. Lee C. S. (2011). 7-ketocholesterol induces apoptosis in differentiated PC12 cells via reactive oxygen species-dependent activation of NF-κB and Akt pathways. Neurochem. Int. 58, 52– 59. 10.1016/j.neuint.2010.10.012 21035514 · DOI
  94. Jaya Prasanthi R. P. Schommer E. Thomasson S. Thompson A. Feist G. Ghribi O. (2008). Regulation of beta-amyloid levels in the brain of cholesterol-fed rabbit, a model system for sporadic Alzheimer’s disease. Mech. Ageing Dev. 129, 649– 655. 10.1016/j.mad.2008.09.002 18845178 PMC2629555 · DOI
  95. Jeitner T. M. Voloshyna I. Reiss A. B. (2011). Oxysterol derivatives of cholesterol in neurodegenerative disorders. Curr. Med. Chem. 18, 1515– 1525. 10.2174/092986711795328445 21428891 · DOI
  96. Jenner A. M. Lim W. L. Ng M. P. Wenk M. R. Shui G. Sharman M. J.. (2010). The effect of APOE genotype on brain levels of oxysterols in young and old human APOE epsilon2, epsilon3 and epsilon4 knock-in mice. Neuroscience 169, 109– 115. 10.1016/j.neuroscience.2010.04.026 20416362 PMC3991300 · DOI
  97. Jo W. K. Law A. C. Chung S. K. (2014). The neglected co-star in the dementia drama: the putative roles of astrocytes in the pathogeneses of major neurocognitive disorders. Mol. Psychiatry 19, 159– 167. 10.1038/mp.2013.171 24393807 · DOI
  98. Joshi Y. B. Praticò D. (2015). The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer’s disease phenotype. Front. Cell Neurosci. 8: 436. 10.3389/fncel.2014.00436 25642165 PMC4294160 · DOI
  99. Kakio A. Nishimoto S. I. Yanagisawa K. Kozutsumi Y. Matsuzaki K. (2001). Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J. Biol. Chem. 276, 24985– 24990. 10.1074/jbc.m100252200 11342534 · DOI
  100. Kakio A. Nishimoto S. Yanagisawa K. Kozutsumi Y. Matsuzaki K. (2002). Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 41, 7385– 7390. 10.1021/bi0255874 12044171 · DOI
  101. Keene C. D. Cudaback E. Li X. Montine K. S. Montine T. J. (2011). Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer’s disease. Curr. Opin. Neurobiol. 21, 920– 928. 10.1016/j.conb.2011.08.002 21907569 PMC3237894 · DOI · Paper page
  102. Khandelwal P. J. Herman A. M. Moussa C. E. (2011). Inflammation in the early stages of neurodegenerative pathology. J. Neuroimmunol. 238, 1– 11. 10.1016/j.jneuroim.2011.07.002 21820744 PMC3176984 · DOI
  103. Kierdorf K. Wang Y. Neumann H. (2010).. Immune-mediated CNS damage. Results Probl. Cell Differ. 51, 173– 196. 10.1007/400_2008_15 19130024 · DOI
  104. Kim D. H. Frangos J. A. (2008). Effects of amyloid beta-peptides on the lysis tension of lipid bilayer vesicles containing oxysterols. Biophys. J. 95, 620– 628. 10.1529/biophysj.107.114983 18390616 PMC2440435 · DOI
  105. Kim H. A. Miller A. A. Drummond G. R. Thrift A. G. Arumugam T. V. Phan T. G.. (2012). Vascular cognitive impairment and Alzheimer’s disease: role of cerebral hypoperfusion and oxidative stress. Naunyn Schmiedebergs Arch. Pharmacol. 385, 953– 959. 10.1007/s00210-012-0790-7 22872171 · DOI
  106. Kim J. H. Jittiwat J. Ong W. Y. Farooqui A. A. Jenner A. M. (2010). Changes in cholesterol biosynthetic and transport pathways after excitotoxicity. J. Neurochem. 112, 34– 41. 10.1111/j.1471-4159.2009.06449.x 19860851 · DOI
  107. Kim W. S. Chan S. L. Hill A. F. Guillemin G. J. Garner B. (2009b). Impact of 27-hydroxycholesterol on amyloid-beta peptide production and ATP-binding cassette transporter expression in primary human neurons. J. Alzheimers Dis. 16, 121– 131. 10.3233/JAD-2009-0944 19158428 · DOI
  108. Kim W. S. Hill A. F. Fitzgerald M. L. Freeman M. W. Evin G. Garner B. (2011). Wild type and tangier disease ABCA1 mutants modulate cellular amyloid-A production independent of cholesterol efflux activity. J. Alzheimers Dis. 27, 441– 452. 10.3233/JAD-2011-110521 21860089 · DOI
  109. Kim Y. J. Lee C. S. (2010). Tyrosine kinase inhibitor AG126 reduces 7-ketocholesterol-induced cell death by suppressing mitochondria-mediated apoptotic process. Neurochem. Res. 35, 603– 612. 10.1007/s11064-009-0105-7 19957203 · DOI
  110. Kim Y. J. Han J. H. Han E. S. Lee C. S. (2006). 7-Ketocholesterol enhances 1-methyl-4-phenylpyridinium-induced mitochondrial dysfunction and cell death in PC12 cells. J. Neural Transm. 113, 1877– 1885. 10.1007/s00702-006-0486-6 16715209 · DOI
  111. Koldamova R. P. Lefterov I. M. Ikonomovic M. D. Skoko J. Lefterov P. I. Isanski B. A.. (2003). 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J. Biol. Chem. 278, 13244– 13256. 10.1074/jbc.m300044200 12547833 · DOI · Paper page
  112. Koldamova R. Fitz N. F. Lefterov I. (2010). The role of ATP-binding cassette transporter A1 in Alzheimer’s disease and neurodegeneration. Biochim. Biophys. Acta 1801, 824– 830. 10.1016/j.bbalip.2010.02.010 20188211 PMC3712769 · DOI · Paper page
  113. Kölsch H. Heun R. Kerksiek A. Bergmann K. V. Maier W. Lütjohann D. (2004). Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients. Neurosci. Lett. 368, 303– 308. 10.1016/j.neulet.2004.07.031 15364416 · DOI
  114. Kölsch H. Ludwig M. Lütjohann D. Prange W. Rao M. L. (2000). 7alpha-Hydroperoxycholesterol causes CNS neuronal cell death. Neurochem. Int. 36, 507– 512. 10.1016/s0197-0186(99)00157-6 10762087 · DOI
  115. Kölsch H. Ludwig M. Lütjohann D. Rao M. L. (2001). Neurotoxicity of 24-hydroxycholesterol, an important cholesterol elimination product of the brain, may be prevented by vitamin E and estradiol-17beta. J. Neural. Transm. 108, 475– 488. 10.1007/s007020170068 11475014 · DOI
  116. Latta C. H. Brothers H. M. Wilcock D. M. (2014). Neuroinflammation in Alzheimer’s disease; A source of heterogeneity and target for personalized therapy. Neuroscience [Epub ahead of print] 10.1007/978-1-4615-5405-9_3 25286385 PMC4602369 · DOI
  117. Leoni V. Caccia C. (2011). Oxysterols as biomarkers in neurodegenerative diseases. Chem.Phys. Lipids 164, 515– 524. 10.1016/j.chemphyslip.2011.04.002 21515244 · DOI
  118. Leoni V. Masterman T. Mousavi F. S. Wretlind B. Wahlund L. O. Diczfalusy U.. (2004). Diagnostic use of cerebral and extracerebral oxysterols. Clin. Chem. Lab. Med. 42, 186– 191. 10.1515/cclm.2004.034 15061359 · DOI
  119. Leoni V. Masterman T. Patel P. Meaney S. Diczfalusy U. Björkhem I. (2003). Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers. J. Lipid Res. 44, 793– 799. 10.1194/jlr.m200434-jlr200 12562838 · DOI
  120. Lewis J. Dickson D. W. Lin W. L. Chisholm L. Corral A. Jones G.. (2001). Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487– 1491. 10.1126/science.1058189 11520987 · DOI · Paper page
  121. Liu B. Hong J. S. (2003). Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 304, 1– 7. 10.1124/jpet.102.035048 12490568 · DOI · Paper page
  122. Liu Q. Zerbinatti C. V. Zhang J. Hoe H. S. Wang B. Cole S. L.. (2007). Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 56, 66– 78. 10.1016/j.neuron.2007.08.008 17920016 PMC2045076 · DOI · Paper page
  123. Luchsinger J. A. Mayeux R. (2004). Dietary factors and Alzheimer’s disease. Lancet. Neurol. 3, 579– 587. 10.1016/S1474-4422(04)00878-6 15380154 · DOI
  124. Luckhoff H. K. Brand T. van Velden D. P. Kidd M. Fisher L. R. van Rensburg S. J.. (2015). Clinical relevance of apolipoprotein e genotyping based on a family history of Alzheimer’s disease. Curr. Alzheimer Res. 12, 210– 217. 10.2174/1567205012666150302154354 25731628 · DOI
  125. Luque-Contreras D. Carvajal K. Toral-Rios D. Franco-Bocanegra D. Campos-Peña V. (2014). Oxidative stress and metabolic syndrome: cause or consequence of Alzheimer’s disease? Oxid. Med. Cell. Longev. 2014: 497802. 10.1155/2014/497802 24683436 PMC3941786 · DOI
  126. Lyman M. Lloyd D. G. Ji X. Vizcaychipi M. P. Ma D. (2014). Neuroinflammation: the role and consequences. Neurosci. Res. 79, 1– 12. 10.1016/j.neures.2013.10.004 24144733 · DOI
  127. Lütjohann D. Papassotiropoulos A. Björkhem I. Locatelli S. Bagli M. Oehring R. D.. (2000). Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J. Lipid Res. 41, 195– 198. 10681402
  128. Ma M. T. Zhang J. Farooqui A. A. Chen P. Ong W. Y. (2010). Effects of cholesterol oxidation products on exocytosis. Neurosci. Lett. 476, 36– 41. 10.1016/j.neulet.2010.03.078 20380872 · DOI
  129. Ma W. W. Li C. Q. Yu H. L. Zhang D. D. Xi Y. D. Han J.. (2015). The oxysterol 27-hydroxycholesterol increases oxidative stress and regulate nrf2 signaling pathway in astrocyte cells. Neurochem. Res. 40, 758– 766. 10.1007/s11064-015-1524-2 25630716 · DOI
  130. Maezawa I. Maeda N. Montine T. J. Montine K. S. (2006a). Apolipoprotein E-specific innate immune response in astrocytes from targeted replacement mice. J. Neuroinflammation 7, 3– 10. 10.1186/1742-2094-3-10 16603079 PMC1502133 · DOI
  131. Maezawa I. Nivison M. Montine K. S. Maeda N. Montine T. J. (2006b). Neurotoxicity from innate immune response is greatest with targeted replacement of E4 allele of apolipoprotein E gene and is mediated by microglial p38MAPK. FASEB J. 20, 797– 799. 10.1096/fj.05-5423fje 16481366 · DOI
  132. Maezawa I. Zaja-Milatovic S. Milatovic D. Stephen C. Sokal I. Maeda N.. (2006c). Apolipoprotein E isoform-dependent dendritic recovery of hippocampal neurons following activation of innate immunity. J. Neuroinflammation 25, 3– 21. 10.1186/1742-2094-3-21 16934151 PMC1584222 · DOI
  133. Malaplate-Armand C. Florent-Béchard S. Youssef I. Koziel V. Sponne I. Kriem B.. (2006). Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol. Dis. 23, 178– 189. 10.1016/j.nbd.2006.02.010 16626961 · DOI
  134. Manczak M. Anekonda T. S. Henson E. Park B. S. Quinn J. Reddy P. H. (2006). Mitochondria are a direct site of Aβ accumulation in Alzheimer’s disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 15, 1437– 1449. 10.1093/hmg/ddl066 16551656 · DOI · Paper page
  135. Mariani E. Polidori M. C. Cherubini A. Mecocci P. (2005). Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 827, 65– 75. 10.1016/j.jchromb.2005.04.023 16183338 · DOI
  136. Martin I. Grotewiel M. S. (2006). Oxidative damage and age-related functional declines. Mech. Ageing Dev. 127, 411– 423. 10.1016/j.mad.2006.01.008 16527333 · DOI
  137. Martins I. J. Berger T. Sharman M. J. Verdile G. Fuller S. J. Martins R. N. (2009). Cholesterol metabolism and transport in the pathogenesis of Alzheimer’s disease. J. Neurochem. 111, 1275– 1308. 10.1111/j.1471-4159.2009.06408.x 20050287 · DOI
  138. Marwarha G. Dasari B. Prasanthi J. R. Schommer J. Ghribi O. (2010). Leptin reduces the accumulation of Abeta and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices. J. Alzheimers Dis. 19, 1007– 1019. 10.3233/JAD-2010-1298 20157255 PMC2924284 · DOI
  139. Marwarha G. Ghribi O. (2014). Does the oxysterol 27-hydroxycholesterol underlie Alzheimer’s disease-Parkinson’s disease overlap? Exp. Gerontol. [Epub ahead of print] 10.1016/j.exger.2014.09.013 25261765 PMC4377123 · DOI
  140. Marwarha G. Raza S. Prasanthi J. R. Ghribi O. (2013). Gadd153 and NF-κB crosstalk regulates 27-hydroxycholesterol-induced increase in BACE1 and β-amyloid production in human neuroblastoma SH-SY5Y cells. PLoS One 8: e70773. 10.1371/journal.pone.0070773 23951005 PMC3739769 · DOI
  141. Marzolo M. P. Bu G. (2009). Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer’s disease. Semin. Cell Dev. Biol. 20, 191– 200. 10.1016/j.semcdb.2008.10.005 19041409 PMC2691858 · DOI · Paper page
  142. Mateos L. Ismail M. A. Gil-Bea F. J. Leoni V. Winblad B. Björkhem I.. (2011). Upregulation of brain renin angiotensin system by 27-hydroxycholesterol in Alzheimer’s disease. J. Alzheimers Dis. 24, 669– 679. 10.3233/JAD-2011-101512 21297254 · DOI
  143. Mattson M. P. (2004). Pathways towards and away from Alzheimer’s disease. Nature 430, 631– 639. 10.1038/nature02621 15295589 PMC3091392 · DOI · Paper page
  144. Mayeux R. (2003). Epidemiology of neurodegeneration. Annu. Rev. Neurosci. 26, 81– 104. 10.1146/annurev.neuro.26.043002.094919 12574495 · DOI
  145. Mazzetti A. P. Fiorile M. C. Primavera A. Lo Bello M. (2015). Glutathione transferases and neurodegenerative diseases. Neurochem. Int. 82, 10– 18. 10.1016/j.neuint.2015.01.008 25661512 · DOI
  146. McGeer E. G. McGeer P. L. (2010). Neuroinflammation in Alzheimer’s disease and mild cognitive impairment: a field in its infancy. J. Alzheimers Dis. 19, 355– 361. 10.3233/JAD-2010-1219 20061650 · DOI
  147. McLellan M. E. Kajdasz S. T. Hyman B. T. Bacskai B. J. (2003). In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J. Neurosci. 23, 2212– 2217. 12657680 PMC6742052
  148. Meaney S. Heverin M. Panzenboeck U. Ekström L. Axelsson M. Andersson U.. (2007). Novel route for elimination of brain oxysterols across the blood-brain barrier: conversion into 7alpha-hydroxy-3-oxo-4-cholestenoic acid. J. Lipid Res. 48, 944– 951. 10.1194/jlr.m600529-jlr200 17251592 · DOI
  149. Melov S. Adlard P. A. Morten K. Johnson F. Golden T. R. Hinerfeld D.. (2007). Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS One 2: e536. 10.1371/journal.pone.0000536 17579710 PMC1888726 · DOI · Paper page
  150. Michelucci A. Heurtaux T. Grandbarbe L. Morga E. Heuschling P. (2009). Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-beta. J. Neuroimmunol. 210, 3– 12. 10.1016/j.jneuroim.2009.02.003 19269040 · DOI · Paper page
  151. Michikawa M. Gong J. S. Fan Q. W. Sawamura N. Yanagisawa K. (2001). A novel action of alzheimer’s amyloid beta-protein (Abeta): oligomeric Abeta promotes lipid release. J. Neurosci. 21, 7226– 7235. 11549733 PMC6762992
  152. Mitomo H. Chen W. H. Regen S. L. (2009). Oxysterol-induced rearrangement of the liquid-ordered phase: a possible link to Alzheimer’s disease? J. Am. Chem. Soc. 131, 12354– 12357. 10.1021/ja904308y 19658396 PMC2748238 · DOI
  153. Morales I. Jiménez J. M. Mancilla M. Maccioni R. B. (2013). Tau oligomers and fibrils induce activation of microglial cells. J. Alzheimers Dis. 37, 849– 856. 10.3233/JAD-131843 23948931 · DOI · Paper page
  154. Mori T. Paris D. Town T. Rojiani A. M. Sparks D. L. Delledonne A.. (2001). Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice. J. Neuropathol. Exp. Neurol. 60, 778– 785. 11487052
  155. Mrak R. E. (2012). Microglia in Alzheimer brain: a neuropathological perspective. Int. J. Alzheimers Dis. 2012: 165021. 10.1155/2012/165021 22655212 PMC3359674 · DOI
  156. Mrak R. E. Griffin W. S. (2005). Glia and their cytokines in progression of neurodegeneration. Neurobiol. Aging 26, 349– 354. 10.1016/j.neurobiolaging.2004.05.010 15639313 · DOI · Paper page
  157. Mungarro-Menchaca X. Ferrera P. Morán J. Arias C. (2002). beta-Amyloid peptide induces ultrastructural changes in synaptosomes and potentiates mitochondrial dysfunction in the presence of ryanodine. J. Neurosci. Res. 68, 89– 96. 10.1002/jnr.10193 11933053 · DOI
  158. Murphy P. G. Borthwick L. S. Johnston R. S. Kuchel G. Richardson P. M. (1999). Nature of the retrograde signal from injured nerves that induces interleukin-6 mRNA in neurons. J. Neurosci. 19, 3791– 3800. 10234011 PMC6782706
  159. Naylor R. Hill A. F. Barnham K. J. (2008). Neurotoxicity in Alzheimer’s disease: is covalently crosslinked A beta responsible? Eur. Biophys. J. 37, 265– 268. 10.1007/s00249-007-0243-2 18064449 · DOI
  160. Nelson T. J. Alkon D. L. (2005). Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide. J. Biol. Chem. 280, 7377– 7387. 10.1074/jbc.m409071200 15591071 · DOI
  161. Nieweg K. Schaller H. Pfrieger F. W. (2009). Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. J. Neurochem. 109, 125– 134. 10.1111/j.1471-4159.2009.05917.x 19166509 · DOI · Paper page
  162. Noguchi N. Saito Y. Urano Y. (2014). Diverse functions of 24(S)-hydroxycholesterol in the brain. Biochem. Biophys. Res. Commun. 446, 692– 696. 10.1016/j.bbrc.2014.02.010 24530911 · DOI
  163. Nury T. Samadi M. Zarrouk A. Riedinger J. M. Lizard G. (2013). Improved synthesis and in vitro evaluation of the cytotoxic profile of oxysterols oxidized at C4 (4α- and 4β-hydroxycholesterol) and C7 (7-ketocholesterol, 7α- and 7β-hydroxycholesterol) on cells of the central nervous system. Eur. J. Med. Chem. 70, 558– 567. 10.1016/j.ejmech.2013.09.028 24211631 · DOI
  164. Okabe A. Urano Y. Itoh S. Suda N. Kotani R. Nishimura Y.. (2013). Adaptive responses induced by 24S-hydroxycholesterol through liver X receptor pathway reduce 7-ketocholesterol-caused neuronal cell death. Redox Biol. 2, 28– 35. 10.1016/j.redox.2013.11.007 24371802 PMC3871289 · DOI
  165. Panza F. D’Introno A. Colacicco A. M. Capurso C. Pichichero G. Capurso S. A.. (2006). Lipid metabolism in cognitive decline and dementia. Brain Res. Rev. 51, 275– 292. 10.1016/j.brainresrev.2005.11.007 16410024 · DOI
  166. Papassotiropoulos A. Lambert J. C. Wavrant-De Vrièze F. Wollmer M. A. von der Kammer H. Streffer J. R.. (2005). Cholesterol 25-hydroxylase on chromosome 10q is a susceptibility gene for sporadic Alzheimer’s disease. Neurodegener. Dis. 2, 233– 241. 10.1159/000090362 16909003 · DOI · Paper page
  167. Papassotiropoulos A. Lütjohann D. Bagli M. Locatelli S. Jessen F. Buschfort R.. (2002). 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J. Psychiatr. Res. 36, 27– 32. 10.1016/s0022-3956(01)00050-4 11755458 · DOI
  168. Perry V. H. Nicoll J. A. Holmes C. (2010). Microglia in neurodegenerative disease. Nat. Rev. Neurol. 6, 193– 201. 10.1038/nrneurol.2010.17 20234358 · DOI · Paper page
  169. Phan H. T. Hata T. Morita M. Yoda T. Hamada T. Vestergaard M. C.. (2013). The effect of oxysterols on the interaction of Alzheimer’s amyloid beta with model membranes. Biochim. Biophys. Acta 1828, 2487– 2495. 10.1016/j.bbamem.2013.06.021 23800382 · DOI
  170. Popescu B. O. Toescu E. C. Popescu L. M. Bajenaru O. Muresanu D. F. Schultzberg M.. (2009). Blood-brain barrier alterations in ageing and dementia. J. Neurol. Sci. 283, 99– 106. 10.1016/j.jns.2009.02.321 19264328 · DOI
  171. Prasanthi J. R. Huls A. Thomasson S. Thompson A. Schommer E. Ghribi O. (2009). Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on beta-amyloid precursor protein levels and processing in human neuroblastoma SH-SY5Y cells. Mol. Neurodegener. 4: 1. 10.1186/1750-1326-4-1 19126211 PMC2654562 · DOI
  172. Puglielli L. Friedlich A. L. Setchell K. D. Nagano S. Opazo C. Cherny R. A.. (2005). Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. J. Clin. Invest. 115, 2556– 2563. 10.1172/JCI23610 16127459 PMC1190368 · DOI
  173. Puglielli L. Konopka G. Pack-Chung E. Ingano L. A. Berezovska O. Hyman B. T.. (2001). Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 3, 905– 912. 10.1038/ncb1001-905 11584272 · DOI · Paper page
  174. Puglielli L. Tanzi R. E. Kovacs D. M. (2003). Alzheimer’s disease: the cholesterol connection. Nat. Neurosci. 6, 345– 351. 10.1038/nn0403-345 12658281 · DOI · Paper page
  175. Qiu L. Buie C. Reay A. Vaughn M. W. Cheng K. H. (2011). Molecular dynamics simulations reveal the protective role of cholesterol in β-amyloid protein-induced membrane disruptions in neuronal membrane mimics. J. Phys. Chem. B. 115, 9795– 9812. 10.1021/jp2012842 21740063 PMC3163122 · DOI
  176. Quintanilla R. A. Orellana J. A. von Bernhardi R. (2012). Understanding risk factors for Alzheimer’s disease: interplay of neuroinflammation, connexin-based communication and oxidative stress. Arch. Med. Res. 43, 632– 644. 10.1016/j.arcmed.2012.10.016 23142264 · DOI
  177. Raber J. Huang Y. Ashfordm J. W. (2004). ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol. Aging 25, 641– 650. 10.1016/j.neurobiolaging.2003.12.023 15172743 · DOI · Paper page
  178. Račková L. (2013). Cholesterol load of microglia: contribution of membrane architecture changes to neurotoxic power? Arch Biochem Biophys. 537, 91– 103. 10.1016/j.abb.2013.06.015 23831332 · DOI
  179. Ramesh G. MacLean A. G. Philipp M. T. (2013). Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration and neuropathic pain. Mediators Inflamm. 2013: 480739. 10.1155/2013/480739 23997430 PMC3753746 · DOI · Paper page
  180. Reddy P. H. (2011). Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria and synaptic deprivation in Alzheimer’s disease. Brain Res. 1415, 136– 148. 10.1016/j.brainres.2011.07.052 21872849 PMC3176990 · DOI
  181. Reddy P. H. Beal M. F. (2005). Are mitochondria critical in the pathogenesis of Alzheimer’s disease? Brain Res. Brain Res. Rev. 49, 618– 632. 10.1016/j.brainresrev.2005.03.004 16269322 · DOI
  182. Reddy P. H. Beal M. F. (2008). Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer’s disease. Trends Mol. Med. 14, 45– 53. 10.1016/j.molmed.2007.12.002 18218341 PMC3107703 · DOI · Paper page
  183. Reddy P. H. McWeeney S. Park B. S. Manczak M. Gutala R. V. Partovi D.. (2004). Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer’s disease. Hum. Mol. Genet. 13, 1225– 1240. 10.1093/hmg/ddh140 15115763 · DOI
  184. Reed T. T. (2011). Lipid peroxidation and neurodegenerative disease. Free Radic. Biol. Med. 51, 1302– 1319. 10.1016/j.freeradbiomed.2011.06.027 21782935 · DOI
  185. Refolo L. M. Malester B. LaFrancois J. Bryant-Thomas T. Wang R. Tint G. S.. (2000). Hypercholesterolemia accelerates the Alzheimer’s amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 4, 321– 331. 10.1006/nbdi.2000.0304 10964604 · DOI · Paper page
  186. Reid P. C. Urano Y. Kodama T. Hamakubo T. (2007). Alzheimer’s disease: cholesterol, membrane rafts, isoprenoids and statins. J. Cell Mol. Med. 11, 383– 392. 10.1111/j.1582-4934.2007.00054.x 17635634 PMC3922347 · DOI
  187. Resende R. Moreira P. I. Proença T. Deshpande A. Busciglio J. Pereira C.. (2008). Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. Free Radic. Biol. Med. 44, 2051– 2057. 10.1016/j.freeradbiomed.2008.03.012 18423383 · DOI · Paper page
  188. Reynolds A. Laurie C. Mosley R. L. Gendelman H. E. (2007). Oxidative stress and the pathogenesis of neurodegenerative disorders. Int Rev Neurobiol. 82, 297– 325. 10.1016/s0074-7742(07)82016-2 17678968 · DOI
  189. Rezai-Zadeh K. Gate D. Gowing G. Town T. (2011). How to get from here to there: macrophage recruitment in Alzheimer’s disease. Curr. Alzheimer Res. 8, 156– 163. 10.2174/1567211213451662050 21345166 PMC3086574 · DOI
  190. Rosales-Corral S. Reiter R. J. Tan D. X. Ortiz G. G. Lopez-Armas G. (2010). Functional aspects of redox control during neuroinflammation. Antioxid Redox Signal. 13, 193– 247. 10.1089/ars.2009.2629 19951033 · DOI
  191. Roßner S. Lange-Dohna C. Zeitschel U. Perez-Polo J. R. (2005). Alzheimer’s disease β-secretase BACE1 is not a neuron-specific enzyme. J. Neurochem. 92, 226– 234. 10.1111/j.1471-4159.2004.02857.x 15663471 · DOI
  192. Royer M. C. Lemaire-Ewing S. Desrumaux C. Monier S. Pais de Barros J. P. Athias A.. (2009). 7-ketocholesterol incorporation into sphingolipid/cholesterol-enriched (lipid raft) domains is impaired by vitamin E: a specific role for alpha-tocopherol with consequences on cell death. J. Biol. Chem. 284, 15826– 15834. 10.1074/jbc.m808641200 19351882 PMC2708879 · DOI
  193. Rubio-Perez J. M. Morillas-Ruiz J. M. (2012). A review: inflammatory process in Alzheimer’s disease, role of cytokines. ScientificWorldJournal. 2012: 756357. 10.1100/2012/756357 22566778 PMC3330269 · DOI
  194. Sagare A. Deane R. Bell R. D. Johnson B. Hamm K. Pendu R.. (2007). Clearance of amyloid-beta by circulating lipoprotein receptors. Nat. Med. 13, 1029– 1031. 10.1038/nm1635 17694066 PMC2936449 · DOI · Paper page
  195. Saint-Pol J. Candela P. Boucau M. C. Fenart L. Gosselet F. (2013). Oxysterols decrease apical-to-basolateral transport of Aß peptides via an ABCB1-mediated process in an in vitro Blood-brain barrier model constituted of bovine brain capillary endothelial cells. Brain Res. 1517, 1– 15. 10.1016/j.brainres.2013.04.008 23603412 · DOI · Paper page
  196. Saint-Pol J. Vandenhaute E. Boucau M. C. Candela P. Dehouck L. Cecchelli R.. (2012). Brain pericytes ABCA1 expression mediates cholesterol efflux but not cellular amyloid-β peptide accumulation. J. Alzheimers Dis. 30, 489– 503. 10.3233/JAD-2012-112090 22433669 · DOI · Paper page
  197. Schipper H. M. (2011). Apolipoprotein E: implications for AD neurobiology, epidemiology and risk assessment. Neurobiol. Aging 32, 778– 790. 10.1016/j.neurobiolaging.2009.04.021 19482376 · DOI
  198. Schönknecht P. Lütjohann D. Pantel J. Bardenheuer H. Hartmann T. von Bergmann K.. (2002). Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer’s disease compared to healthy controls. Neurosci. Lett. 324, 83– 85. 10.1016/s0304-3940(02)00164-7 11983301 · DOI
  199. Shafaati M. Marutle A. Pettersson H. Lövgren-Sandblom A. Olin M. Pikuleva I.. (2011). Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer’s patients with the Swedish APP 670/671 mutation. J. Lipid Res. 52, 1004– 1010. 10.1194/jlr.m014548 21335619 PMC3073459 · DOI
  200. Sharma S. Prasanthi R. P. J. Schommer E. Feist G. Ghribi O. (2008). Hypercholesterolemia-induced Abeta accumulation in rabbit brain is associated with alteration in IGF-1 signaling. Neurobiol. Dis. 32, 426– 432. 10.1016/j.nbd.2008.08.002 18775495 PMC2658815 · DOI

200 of 251 shown

Cited by

Sorted by citations

Metadata

Authors
Gamba, P., Testa, G., Gargiulo, S., Staurenghi, E., Poli, G., & Leonarduzzi, G.
Venue
Frontiers in Aging Neuroscience
Publisher
Frontiers Media SA
Published
2015-06-19
Volume
7
ISSN
1663-4365
DOI
10.3389/fnagi.2015.00119
PMC
PMC4473000
Cited by
180
References
43

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review